Comparative evaluation of morphine, pentazocine and ciramadol in postaddicts

K. L. Preston, George Bigelow, I. A. Liebson

Research output: Contribution to journalArticle

Abstract

The subjective, physiological and behavioral effects of morphine, pentazocine and ciramadol, an opioid agonist/antagonist, were studied in adult male nondependent opioid abusers living on a clinical research ward. Fifteen subjects were assigned randomly to one of three groups. Each group received, by i.m. injection, placebo and three doses of one active drug, twice in randomized block order under double-blind conditions in 4.5-hr experimental sessions. Physiological measures did not differentiate between the three drugs. All three drugs decreased respiratory rate and pupil diameter and increased blood pressure. However, morphine, ciramadol and pentazocine produced different profiles on the subjective effect measures. All three drugs increased 'liking', 'good effects', 'any effects' and 'high' subjective effect scales. Pentazocine increased subjective 'bad effects' scale scores and scales measuring dysphoria and sedation. Observers reported significant behavioral changes after administration of morphine and pentazocine, but not after ciramadol. Overall, the effects of morphine (7.5, 15 and 30 mg) and pentazocine (22.5, 45 and 90 mg) were dose-related. Although pentazocine produced increases in scales that indicated negative subjective effects, it also produced significant changes in most self-report measures that were increased by morphine, including liking and good effects scales. The effects of ciramadol were not dose-related, with all three doses (30, 60 and 120 mg) producing effects approximately equivalent to morphine 15 mg. Thus, ciramadol exhibited a ceiling effect of the opioid agonist/antagonist.

Original languageEnglish (US)
Pages (from-to)900-910
Number of pages11
JournalJournal of Pharmacology and Experimental Therapeutics
Volume240
Issue number3
StatePublished - 1987

Fingerprint

Pentazocine
Morphine
Narcotic Antagonists
Pharmaceutical Preparations
Pupil
Respiratory Rate
Self Report
Opioid Analgesics
ciramadol
Placebos
Blood Pressure
Injections
Research

ASJC Scopus subject areas

  • Pharmacology

Cite this

Comparative evaluation of morphine, pentazocine and ciramadol in postaddicts. / Preston, K. L.; Bigelow, George; Liebson, I. A.

In: Journal of Pharmacology and Experimental Therapeutics, Vol. 240, No. 3, 1987, p. 900-910.

Research output: Contribution to journalArticle

@article{c6e86bd4fc234cf9807f610ff1864b32,
title = "Comparative evaluation of morphine, pentazocine and ciramadol in postaddicts",
abstract = "The subjective, physiological and behavioral effects of morphine, pentazocine and ciramadol, an opioid agonist/antagonist, were studied in adult male nondependent opioid abusers living on a clinical research ward. Fifteen subjects were assigned randomly to one of three groups. Each group received, by i.m. injection, placebo and three doses of one active drug, twice in randomized block order under double-blind conditions in 4.5-hr experimental sessions. Physiological measures did not differentiate between the three drugs. All three drugs decreased respiratory rate and pupil diameter and increased blood pressure. However, morphine, ciramadol and pentazocine produced different profiles on the subjective effect measures. All three drugs increased 'liking', 'good effects', 'any effects' and 'high' subjective effect scales. Pentazocine increased subjective 'bad effects' scale scores and scales measuring dysphoria and sedation. Observers reported significant behavioral changes after administration of morphine and pentazocine, but not after ciramadol. Overall, the effects of morphine (7.5, 15 and 30 mg) and pentazocine (22.5, 45 and 90 mg) were dose-related. Although pentazocine produced increases in scales that indicated negative subjective effects, it also produced significant changes in most self-report measures that were increased by morphine, including liking and good effects scales. The effects of ciramadol were not dose-related, with all three doses (30, 60 and 120 mg) producing effects approximately equivalent to morphine 15 mg. Thus, ciramadol exhibited a ceiling effect of the opioid agonist/antagonist.",
author = "Preston, {K. L.} and George Bigelow and Liebson, {I. A.}",
year = "1987",
language = "English (US)",
volume = "240",
pages = "900--910",
journal = "Journal of Pharmacology and Experimental Therapeutics",
issn = "0022-3565",
publisher = "American Society for Pharmacology and Experimental Therapeutics",
number = "3",

}

TY - JOUR

T1 - Comparative evaluation of morphine, pentazocine and ciramadol in postaddicts

AU - Preston, K. L.

AU - Bigelow, George

AU - Liebson, I. A.

PY - 1987

Y1 - 1987

N2 - The subjective, physiological and behavioral effects of morphine, pentazocine and ciramadol, an opioid agonist/antagonist, were studied in adult male nondependent opioid abusers living on a clinical research ward. Fifteen subjects were assigned randomly to one of three groups. Each group received, by i.m. injection, placebo and three doses of one active drug, twice in randomized block order under double-blind conditions in 4.5-hr experimental sessions. Physiological measures did not differentiate between the three drugs. All three drugs decreased respiratory rate and pupil diameter and increased blood pressure. However, morphine, ciramadol and pentazocine produced different profiles on the subjective effect measures. All three drugs increased 'liking', 'good effects', 'any effects' and 'high' subjective effect scales. Pentazocine increased subjective 'bad effects' scale scores and scales measuring dysphoria and sedation. Observers reported significant behavioral changes after administration of morphine and pentazocine, but not after ciramadol. Overall, the effects of morphine (7.5, 15 and 30 mg) and pentazocine (22.5, 45 and 90 mg) were dose-related. Although pentazocine produced increases in scales that indicated negative subjective effects, it also produced significant changes in most self-report measures that were increased by morphine, including liking and good effects scales. The effects of ciramadol were not dose-related, with all three doses (30, 60 and 120 mg) producing effects approximately equivalent to morphine 15 mg. Thus, ciramadol exhibited a ceiling effect of the opioid agonist/antagonist.

AB - The subjective, physiological and behavioral effects of morphine, pentazocine and ciramadol, an opioid agonist/antagonist, were studied in adult male nondependent opioid abusers living on a clinical research ward. Fifteen subjects were assigned randomly to one of three groups. Each group received, by i.m. injection, placebo and three doses of one active drug, twice in randomized block order under double-blind conditions in 4.5-hr experimental sessions. Physiological measures did not differentiate between the three drugs. All three drugs decreased respiratory rate and pupil diameter and increased blood pressure. However, morphine, ciramadol and pentazocine produced different profiles on the subjective effect measures. All three drugs increased 'liking', 'good effects', 'any effects' and 'high' subjective effect scales. Pentazocine increased subjective 'bad effects' scale scores and scales measuring dysphoria and sedation. Observers reported significant behavioral changes after administration of morphine and pentazocine, but not after ciramadol. Overall, the effects of morphine (7.5, 15 and 30 mg) and pentazocine (22.5, 45 and 90 mg) were dose-related. Although pentazocine produced increases in scales that indicated negative subjective effects, it also produced significant changes in most self-report measures that were increased by morphine, including liking and good effects scales. The effects of ciramadol were not dose-related, with all three doses (30, 60 and 120 mg) producing effects approximately equivalent to morphine 15 mg. Thus, ciramadol exhibited a ceiling effect of the opioid agonist/antagonist.

UR - http://www.scopus.com/inward/record.url?scp=0023131580&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0023131580&partnerID=8YFLogxK

M3 - Article

C2 - 3559982

AN - SCOPUS:0023131580

VL - 240

SP - 900

EP - 910

JO - Journal of Pharmacology and Experimental Therapeutics

JF - Journal of Pharmacology and Experimental Therapeutics

SN - 0022-3565

IS - 3

ER -